Sugiu, Kazuhisa
Tazawa, Hiroshi https://orcid.org/0000-0003-4658-1050
Hasei, Joe https://orcid.org/0000-0002-4028-0786
Yamakawa, Yasuaki https://orcid.org/0000-0002-4210-759X
Omori, Toshinori
Komatsubara, Tadashi
Mochizuki, Yusuke https://orcid.org/0000-0002-3415-2796
Kondo, Hiroya https://orcid.org/0000-0002-4642-5448
Osaki, Shuhei https://orcid.org/0000-0002-0498-5017
Fujiwara, Tomohiro https://orcid.org/0000-0003-4257-9180
Yoshida, Aki https://orcid.org/0000-0002-4790-933X
Kunisada, Toshiyuki https://orcid.org/0000-0002-1775-850X
Ueda, Koji https://orcid.org/0000-0001-9066-4959
Urata, Yasuo
Kagawa, Shunsuke https://orcid.org/0000-0002-3610-8211
Ozaki, Toshifumi
Fujiwara, Toshiyoshi https://orcid.org/0000-0002-5377-6051
Funding for this research was provided by:
The Japan Agency for Medical Research and Development (17ck0106285h001)
The Ministry of Education, Culture, Sports, Science, and Technology, Japan (25293238, 16H05416, 25293323, 25462333, 16K10862, 15K10446, 16K10596)
Article History
Received: 17 December 2020
Accepted: 31 May 2021
First Online: 10 June 2021
Declarations
:
: Y. Urata is President and CEO of Oncolys BioPharma, Inc. H. Tazawa and T. Fujiwara are consultants of Oncolys BioPharma, Inc. The other authors have no potential conflicts of interest to disclose.